UroGen Pharma Ltd.
URGNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. The company carries a $2.16B market cap, placing it firmly in the mid-cap category. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Market Cap
$2.16B
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
15.78
EPS (TTM)
$-1.97
EPS (Fwd)
$2.79
ROE
—
ROA
-18.1%
Cash
$108.0M
Total Debt
$196.1M
Free CF
-$107.0M
52W Change
113.1%
Annual Financials
Cash vs Debt
Where URGN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, URGN finished 46.59% above its 150-day moving average ($29.60) and 55.19% above its 200-day moving average ($27.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is URGN overbought or oversold?
At the September 2, 2026 close, URGN's RSI(14) was 25.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
UroGen Pharma Ltd. carries $196.1M in total debt against $108.0M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$107.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $64.4M (2022) to $109.8M (2025), reflecting a 71% increase over the period.
With a beta above 1.5, URGN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for UroGen Pharma Ltd. and its sector.